Fluorine in Medicine vs. PFAS: Understanding the Critical Distinction Between Therapeutic Safety and Environmental Risk
The word “fluorine” has recently become a source of public confusion—celebrated in dental care for decades, yet simultaneously vilified as part of a class of persistent industrial chemicals linked to serious health concerns. This duality stems not from fluorine itself, but from how it is chemically bound and used. Clinically administered fluorinated drugs—including fluoride toothpaste, fluoride varnishes, and certain antineoplastic or antimicrobial agents—are fundamentally different from per- and polyfluoroalkyl substances (PFAS), often dubbed “forever chemicals.” Conflating the two risks undermining evidence-based medicine while diverting attention from genuine environmental hazards.
Fluorinated pharmaceuticals refer to compounds containing carbon–fluorine bonds or formulations that incorporate inorganic fluoride salts—such as sodium fluoride or sodium monofluorophosphate—as active ingredients. These agents have undergone rigorous clinical evaluation over more than 50 years. In dentistry, for example, topical fluoride application remains a cornerstone of caries prevention. According to the *Expert Consensus on Clinical Application of Fluoride Varnish*, frequency of application should be risk-stratified: once annually for low-caries-risk individuals and two to four times per year for those at high risk. When used within these evidence-based parameters, fluoride varnish poses no risk of dental fluorosis—a safety profile consistently confirmed across large-scale longitudinal studies.
In stark contrast, PFAS encompasses over 10,000 synthetic compounds characterized by multiple carbon–fluorine bonds, rendering them extraordinarily resistant to environmental degradation. Key representatives include perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS). The International Agency for Research on Cancer (IARC) classifies PFOA as carcinogenic to humans (Group 1) and PFOS as possibly carcinogenic (Group 2B). Unlike targeted therapeutic fluorination, PFAS exposure occurs broadly and unintentionally—through contaminated drinking water, food packaging, nonstick cookware, waterproof textiles, and even some cosmetics. A 2023 systematic review published in *Environmental and Occupational Medicine* synthesized findings linking PFAS exposure to hepatotoxicity, nephrotoxicity, immunosuppression, reproductive dysfunction, metabolic dysregulation, neurotoxicity, and carcinogenesis.
Emerging research also raises questions about the pharmacokinetic behavior of PFAS when intentionally included in medicinal products. A 2026 study in *Environment International* investigated perfluorohexyloctane (F6H8)—a PFAS compound used as an ophthalmic lubricant—using human HepaRG hepatocytes to model systemic exposure. Researchers observed that F6H8 undergoes biotransformation in liver cells into a metabolite structurally consistent with perfluorohexanoic acid, a carboxylated PFAS derivative. Moreover, F6H8 exhibited concentration-dependent, non-monotonic effects on lipid metabolism: low concentrations suppressed lipogenesis, whereas higher concentrations induced intracellular lipid accumulation—a pattern suggestive of disrupted hepatic homeostasis. These findings underscore that even PFAS compounds approved for specific medical indications warrant long-term, mechanism-driven safety assessment.
For clinicians and patients alike, three principles are essential:
First, distinguish between regulated fluorinated therapeutics and unregulated PFAS exposure. Fluoride toothpaste and dental varnishes—subject to national drug regulatory oversight and used as directed—pose no established safety concerns. Conversely, daily exposure to PFAS leaching from consumer goods (e.g., stain-resistant fabrics, grease-proof food containers, or nonstick surfaces) represents an avoidable environmental burden with accumulating toxicological evidence.
Second, maintain vigilant monitoring for patients on long-term fluorinated medications—particularly those with narrow therapeutic indices or potential for cumulative exposure, such as certain fluoropyrimidine-based chemotherapies or extended-course antifungal regimens. Regular clinical follow-up, including organ function testing and risk–benefit reassessment, is critical.
Third, recognize the regulatory divergence: traditional fluorinated drugs benefit from decades of real-world safety data and robust pharmacovigilance frameworks. Meanwhile, PFAS—due to its environmental persistence and multisystem toxicity—is increasingly subject to stringent controls in China, including inclusion in the National List of Emerging Pollutants and tightening limits in drinking water standards. However, the long-term clinical implications of PFAS-containing pharmaceuticals remain incompletely characterized and require dedicated, prospective investigation.
Public health messaging must therefore emphasize nuance—not alarm. Fluorine, as an element, is neither inherently harmful nor universally benign. Its biological impact depends entirely on molecular context, route of exposure, dose, and duration. Clinicians play a pivotal role in reinforcing this distinction, guiding appropriate use of fluorinated therapeutics while advocating for broader policy action to mitigate PFAS contamination in the environment and supply chain.